Login to Your Account

Bioverativ, Bicycle in $424.2M deal targeting hemophilia, sickle cell

By Nuala Moran
Staff Writer

Wednesday, September 6, 2017

LONDON – Bioverativ Inc. is teaming up with Bicycle Therapeutics Ltd. to develop new treatments for hemophilia and sickle cell disease, in a deal worth $424.2 million to Bicycle if two products make it to market.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription